BUZZ-Australia's Neuren Pharma climbs after Canada approves drug trial

Reuters12-22 07:28

** Shares of Australia's Neuren Pharmaceuticals NEU.AX rise as much as 2.8% to A$20.13

** Biopharma firm announces Health Canada has approved its Clinical Trial Application $(CTA)$ for the Koala Phase 3 clinical trial of NNZ-2591 in treatment of Phelan-McDermid syndrome, a rare genetic condition that affects brain development

** CTA approval enables inclusion of clinical trial sites in Canada

** NEU up 59.4% YTD

Health Canada has approved Neuren’s Clinical Trial Application (CTA) for the Koala Phase 3

(Reporting by Keshav Singh Chundawat in Bengaluru; Editing by Edmund Klamann)

((Keshav.singhchundawat@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593762001?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-22 07:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593762001","market":"us","top_or_hot":-1,"title":"BUZZ-Australia's Neuren Pharma climbs after Canada approves drug trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Australia's Neuren Pharma climbs after Canada approves drug trial</title></head><body><p>** Shares of Australia's <a href=\"https://laohu8.com/S/NEU.AU\">Neuren Pharmaceuticals</a> <span>NEU.AX</span> rise as much as 2.8% to A$20.13</p><p>** Biopharma firm <span>announces</span> Health Canada has approved its Clinical Trial Application <a href=\"https://laohu8.com/S/CTA\">$(CTA)$</a> for the Koala Phase 3 clinical trial of NNZ-2591 in treatment of Phelan-McDermid syndrome, a rare genetic condition that affects brain development</p><p>** CTA approval enables inclusion of clinical trial sites in Canada</p><p>** NEU up 59.4% YTD</p><p>Health Canada has approved Neuren’s Clinical Trial Application (CTA) for the Koala Phase 3 </p><p> (Reporting by Keshav Singh Chundawat in Bengaluru; Editing by Edmund Klamann)</p><p> ((Keshav.singhchundawat@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Australia's Neuren Pharma climbs after Canada approves drug trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Australia's Neuren Pharma climbs after Canada approves drug trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-22 07:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Australia's Neuren Pharma climbs after Canada approves drug trial</title></head><body><p>** Shares of Australia's <a href=\"https://laohu8.com/S/NEU.AU\">Neuren Pharmaceuticals</a> <span>NEU.AX</span> rise as much as 2.8% to A$20.13</p><p>** Biopharma firm <span>announces</span> Health Canada has approved its Clinical Trial Application <a href=\"https://laohu8.com/S/CTA\">$(CTA)$</a> for the Koala Phase 3 clinical trial of NNZ-2591 in treatment of Phelan-McDermid syndrome, a rare genetic condition that affects brain development</p><p>** CTA approval enables inclusion of clinical trial sites in Canada</p><p>** NEU up 59.4% YTD</p><p>Health Canada has approved Neuren’s Clinical Trial Application (CTA) for the Koala Phase 3 </p><p> (Reporting by Keshav Singh Chundawat in Bengaluru; Editing by Edmund Klamann)</p><p> ((Keshav.singhchundawat@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NEU.AU","symbol_name":"NEUREN PHARMACEUTICALS LTD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251221:nL6N3XR07S:1","article_id":"2593762001","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593762001","pubTimestamp":1766359706,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Australia's Neuren Pharma climbs after Canada approves drug trial** Shares of Australia's Neuren Pharmaceuticals NEU.AX rise as much as 2.8% to A$20.13** Biopharma firm announces Health Canada ha","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NEU.AU":"NEUREN PHARMACEUTICALS LTD","BK7508":"医药生物股","BK7096":"制药"},"translate_title":"加拿大批准药物试验后，澳大利亚Neuren Pharma股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEU.AU":0.9},"content_text":"BUZZ-Australia's Neuren Pharma climbs after Canada approves drug trial** Shares of Australia's Neuren Pharmaceuticals NEU.AX rise as much as 2.8% to A$20.13** Biopharma firm announces Health Canada has approved its Clinical Trial Application $(CTA)$ for the Koala Phase 3 clinical trial of NNZ-2591 in treatment of Phelan-McDermid syndrome, a rare genetic condition that affects brain development** CTA approval enables inclusion of clinical trial sites in Canada** NEU up 59.4% YTDHealth Canada has approved Neuren’s Clinical Trial Application (CTA) for the Koala Phase 3  (Reporting by Keshav Singh Chundawat in Bengaluru; Editing by Edmund Klamann) ((Keshav.singhchundawat@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593762001","isCrawlerRequest":true}